title: Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa.
abstract: Herpes simplex virus type-2 (HSV2) infection increases HIV transmission. We explore the impact of a potential prophylactic HSV2 vaccination on HIV incidence in Africa using STDSIM an individual-based model. A campaign that achieved 70% coverage over 5 years with a vaccine that reduced susceptibility to HSV2 acquisition and HSV2 reactivation by 75% for 10 years, reduced HIV incidence by 30-40% after 20 years (range 4-66%). Over 20 years, in most scenarios fewer than 100 vaccinations were required to avert one HIV infection. HSV2 vaccines could have a substantial impact on HIV incidence. Intensified efforts are needed to develop an effective HSV2 vaccine.
authors.affiliation: Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
authors.forename: Esther E
authors.initials: EE
authors.lastname: Freeman
authors.forename: Richard G
authors.initials: RG
authors.lastname: White
authors.forename: Roel
authors.initials: R
authors.lastname: Bakker
authors.forename: Kate K
authors.initials: KK
authors.lastname: Orroth
authors.forename: Helen A
authors.initials: HA
authors.lastname: Weiss
authors.forename: Anne
authors.initials: A
authors.lastname: Buvé
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Hayes
authors.forename: Judith R
authors.initials: JR
authors.lastname: Glynn
mesh_terms: D000293:Adolescent; D000328:Adult; D017954:Africa South of the Sahara / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000453:epidemiology*; D006558:Herpes Genitalis / Q000517:prevention & control*; D022301:Herpes Simplex Virus Vaccines / Q000276:immunology*; D018258:Herpesvirus 2, Human / Q000276:immunology*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D055815:Young Adult
chemical_list: D022301:Herpes Simplex Virus Vaccines